Welcome to the ADC Therapeutics Second Quarter 2021 Financial Results Conference Call. My name is Victor, and I'll be your operator for today's call. At t this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] I will now turn the call over to Amanda Hamilton, Investor Relations Manager. Amanda, you may begin.

Thank you, operator. This morning, we issued a press release announcing our second quarter 2021 financial results and business update. This release is available on the ADCT website at ir.adctherapeutics.com under the press release section. On today's call, Chris Martin, Chief Executive Officer; Jennifer Herron, Chief Commercial Officer; Jay Feingold, Chief Medical Officer; and Jenn Creel, Chief Financial Officer, will discuss recent business highlights and review our second quarter 2021 financial results before opening the call for questions. As a reminder, this conference call may contain forward-looking statements. Such statements are subject to risks and uncertainties. For additional information concerning forward-looking statements and factors that could cause actual results to differ materially from those expressed or implied in these statements, we refer you to the section titled Cautionary Statement Regarding Forward-Looking Statements in Exhibit 99.3 of our report on Form 6-K filed with the U.S. Securities and Exchange Commission earlier today. Such statements speak only as of the date of this conference call, and we expressly disclaim any obligation or undertaking to update these forward-looking statements unless required to do so by applicable law. Today's presentation also includes non-IFRS financial measures. These non-IFRS measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with IFRS. You should refer to the information contained in the company's second quarter earnings release for definitional information and reconciliations of historical non-IFRS measures to the comparable IFRS financial measures. It is now my pleasure to pass the call over to our CEO, Chris Martin. Chris?

Thanks, Amanda. And thank you, everyone, for joining us today. The second quarter was nothing less than transformative for our company, as we received our first accelerated FDA approval and brought ZYNLONTA with its broad label and differentiated profile to this area of high unmet medical need. We achieved key objectives across the board, including commercial, clinical development and corporate development goals. Let's start with our first commercial product. In April, we received accelerated FDA approval for ZYNLONTA, for our first indication in relapsed/refractory DLBCL, and became a fully integrated biopharma company. Today it's early in the launch, and we're pleased with our progress and the positive perception from the physician and payer communities. Jennifer Herron, our Chief Commercial Officer, will share more details about our launch a little later in this call. On the R&D front, we continue to advance our pipeline programs, which we expect to also drive long-term value for the company. We presented new data at ASCO and ICML on a few of our key programs, including updated duration of response for the pivotal ZYNLONTA Phase II LOTIS-2 trial and the Phase I trial of ZYNLONTA in combination with ibrutinib. We also presented encouraging interim data for the Phase II trial of our second program, Cami, in Hodgkin lymphoma. Jay will elaborate further on these, and our other programs in a few moments. We are also focused on expanding our geographic footprint, provide ZYNLONTA to as new patients as possible worldwide. As you know, we formed the joint venture, Overland ADCT BioPharma, to develop and commercialize all of our products, including ZYNLONTA, in Greater China and Singapore. The joint venture has made tremendous progress, including the hire of the CEO, Eric Ku, who has substantial experience in China. Eric and his team are now making rapid progress towards initiating pivotal bridging study. As for Europe, we have recently engaged with EU regulators, and based on that feedback, we plan to submit a marketing authorization occupation to the EMA in the second half of 2021. We are evaluating all of our go-to-market options and look forward to updating you on our plans for Europe when we have more specific details to share. I would now like to turn the call over to Jennifer to provide some insights from the early days of the ZYNLONTA launch. Jennifer?

Thank you, Chris. Good morning, everyone. Let me start with our focus to bring ZYNLONTA to any third-line DLBCL patient who may benefit. We have an exceptional team of seasoned industry professionals who have executed very well with this single objective in mind. To that end, I'm happy to report that the ZYNLONTA launch is off to an encouraging start in its early stages. We are pleased to report ZYNLONTA net sales in the second quarter, of $3.8 million. This represents approximately two months of sales, following approval in late April, and reflects launch-to-date patient demand with no material inventory built. The encouraging early launch performance is the result of the strong execution of our seasoned cross functional team of oncology professionals across medical, market access, marketing, sales and commercial operations, all working together to educate physicians, nurses and pharmacists on ZYNLONTA's differentiated product profile in third-line DLBCL, which remains an area of high unmet medical need. Providing some additional context on the early launch dynamics, our commercial team has engaged all key accounts with patient starts at a significant number of those accounts. A substantial number of NCCN centers have ordered and reordered ZYNLONTA. The differentiated ZYNLONTA product profile, as reflected in our pivotal LOTIS-2 trial, has been well received by both academic and community-based physicians. ZYNLONTA's consistent efficacy across a broad patient population, including heavily pre-treated patients and patients with difficult-to-treat disease, its manageable safety profile and ease of administration, applies equally well to the real-world patient population in both the academic and community settings, resulting in an approximate 50-50 split in terms of accounts ordering ZYNLONTA. Over the next few quarters, we expect a greater proportion of ZYNLONTA volumes to come from community-based physicians. Finally, we have seen significant increases in aided and unaided awareness, reflecting the…

Thank you, Jennifer. Beyond the first approved indication for ZYNLONTA, we are exploring opportunities to expand the addressable patient population into earlier lines of treatment and into additional histologies. As Chris mentioned earlier, updated data from the ZYNLONTA pivotal LOTIS-2 trial were presented at ASCO and ICML. The overall response rate was 48% and a complete response rate, 25%. As of the March 1, 2021 cut-off date, the median duration response increased to 13.4 months for all responders, with durable responses even in high-risk subgroups. In addition, the median duration of response for pre-responding patients was not reached. As a reminder, the patient population of this trial included patients who did not respond to first-line therapy or any prior lines of therapy. Patients who failed CAR-T therapy or stem cell transplant, and patients with high-grade B-cell lymphoma, including those with double hit and triple hit genetics. These results reinforce the efficacy and safety of ZYNLONTA as a monotherapy, a manageable safety profile and its convenient ease of administration. David recently presented at ICML in the LOTIS-2 trial of ZYNLONTA, in combination with ibrutinib for patients with relapsed or refractory DLBCL, or mantle cell lymphoma. Updated Phase I data showed encouraging efficacy and manageable toxicity, with an overall response rate of 67% and a complete response rate of 38% in non-GCB subtype DLBCL patients. Based on interim data from the ongoing Phase II trial, we've decided to amend the protocol to evaluate the administration of ZYNLONTA with every cycle to potentially further enhance efficacy and durability. Based on this additional data, we could potentially pursue a Phase III study in second-line DLBCL, expanding the addressable market and the number of patients who could benefit from ZYNLONTA. The Phase II portion of this trial continues to enroll. Our ongoing confirmatory Phase III…

Thank you, Jay. And good morning, everyone. As reported in the press release issued earlier today, ZYNLONTA's second quarter net sales were $3.8 million, reflecting the two months of ZYNLONTA sales. As of June 30, 2021, we had cash and cash equivalents of approximately $372 million as compared to approximately $383 million as of March 31, 2021. During the quarter, we drew down the last $50 million Tranche from our Deerfield facility, which was contingent upon ZYNLONTA approval. We used approximately $58 million in net cash for operating activities in the second quarter of 2021. R&D expenses were $40 million for the second quarter of 2021 compared to $26 million for the same quarter in 2020. The increase was primarily related to the medical affairs support of the ZYNLONTA launch and the expansion of our ZYNLONTA clinical program and our broad portfolio. Selling and marketing expenses were $15 million for the second quarter of 2021 compared to $4 million for the same quarter of 2020. The increase in selling and marketing reflects the preparations for the ZYNLONTA launch and the ongoing commercial efforts. G&A expenses were $19 million for the second quarter of 2021 compared to $15 million for the same quarter of 2020. The increase was primarily due to the cost of being a public company. Net loss was $73 million for the second quarter of 2021 compared to a net loss of $127 million for the same quarter of 2020. Net loss included share-based compensation expense of $18 million for the second quarter of 2021. Our diluted net loss per share was $0.95 in the second quarter of 2021 compared to a net loss of $2.01 for the same quarter of 2020. Finally, adjusted net loss, a measure that excludes certain items associated with the Deerfield convertible loan and share-based compensation expense, was $54 million for the second quarter of 2021 compared to an adjusted net loss of $32 million in the same quarter of 2020. The increase in adjusted net loss was primarily driven by the investment in the ZYNLONTA launch and our clinical programs. The adjusted diluted net loss per share was $0.70 for the quarter compared to a loss of $0.51 for the same quarter of 2020. With that, I will turn the call back to Chris for closing remarks. Chris?

Thank you, Jay and Jennifer. To conclude, this has been a productive and important first half of 2021. We achieved important milestones, including, of course, the transformative ZYNLONTA approval and launch. Our objectives for the remainder of the year are equally ambitious, and we are well positioned to execute on all aspects of the business. We look forward to updating you on the progress of our launch and our advancing pipeline in the coming quarters. I'm pleased now to open the call to your questions. Operator?

Thank you. [Operator Instructions] Our first question comes from the line of Brian Cheng from Cantor Fitzgerald. You may begin.

Hey, team. Congrats on the [indiscernible] Thanks for taking my question. It's good to see the 50-50 split of academic versus community docs using ZYNLONTA. But can you talk about how that split coincides with your launch strategy and expectations? And given you have a differentiated data set, double-hit, triple-hits up there compared to other recently approved agents, do you see a more concentrated uptick there? And then I have a follow-up. Thanks.

Jennifer?

Yeah. Thanks, Chris. And Brian, thanks for your question. As I mentioned in my remarks, our accounts ordering ZYNLONTA are split 50-50 across academic and community. And I think that's really reflective of the differentiated product profile, our broad third-line indication, ease of administration, and the fact that we haven't seen any significant payer barriers to date. We do believe that the versatility of ZYNLONTA's differentiated profile has enabled both academic and community physicians to identify patients who may benefit from ZYNLONTA. We do, however, expect a greater proportion of patients to come from the community as an increasing number of medical policies are published, and ultimately with our permanent J-code expected in January of 2022. And in terms of your question on double-hit triple-hit subpopulations, from what we've heard actually in the early weeks of launch, physician and patient real-world experience to date has been consistent with the profile, as described in the pivotal LOTIS-2 trial in terms of efficacy, safety and dosing across a broad patient population in third-line DLBCL. So we haven't seen any specific concentration in subgroups. We believe it's being used broadly in alignment with our indication.

Okay. Thank you, Jennifer. And then for Jenn, one quick one. So in the $3.8 million number for ZYNLONTA, how much of that is rolled over from the EAP that you started earlier this year versus organic new patients start? And I know that you don't have inventory built this year. Should we expect any inventory build later this year? Thank you.

Sure. Hi, this is Jenn. Thanks, Brian for the question. We did not have any significant material rollover from the EAP program. And then - I'm sorry, can you remind me of your second question? Sorry.

Should we expect any inventory build later this year?

We're not expecting any material build. The second quarter sales didn't have any material impact from an inventory build, and we're not expecting that in the future.

Great. Terrific. Thank you, Jennifer.

Thank you.

Our next question comes from the line of Matthew Harrison from Morgan Stanley. You may begin.

Great. Good morning. Thanks for taking the questions. Two for me. So I guess, first, on launch dynamics. Can you maybe just talk about - I assume these are all demand patients, and you didn't see any sort of bulks of patients waiting for drug, but maybe if you could just confirm that. And then the second question is just around the ibrutinib combo. It sounds like there's a point here at which you're going to enroll more patients and then be able to speak to regulators about potentially a Phase III program. Maybe you could just talk about when you think you're going to get to that point? Thanks.

Jennifer, do you want to take part one, and Jay, part two?

Yeah, absolutely. Matthew, thanks for the question. Yeah, I can confirm that we don't believe there is any pent-up demand in Q2, largely because of the aggressive nature of the disease. So we do believe that all the $3.8 million in net sales in Q2 reflects real-time patient demand, and more importantly, the unmet medical needs for these patients.

Matthew, with regards to the ibrutinib trial - this is Jay. So we have to amend the trial, which always takes time to not only write, but more importantly, to get to the institutionally DBOs, the IRBs. So that's going to take a bit of time and then we'll reopen for enrollment. And we really want to nail down the appropriate dosing regimen. And just as importantly, we want to make sure we find out with regard to cell biology [ph] So we – we'll take some time to enroll that study. So I'm not anticipating that we'll have much more to say about that study for - into 2022. We'll see how it goes then.

Thank you. [Operator Instructions] Our next question will come from the line of Kennen MacKay from RBC. You may begin.

Hi. Thanks for taking the questions. Maybe initially a question on Cami. After the data at ICML, can you maybe talk at all around any regulatory interactions you've had around plans for an accelerated approval? And I'd want to also hear any KOL feedback you've had on the data, as well as managing the incidence of GBS and whether there's - what the current thinking is around that mechanism and whether there are any sort of any preventative measures or even differences in expected incidents between lymphomas and solid tumors? And then I just have a quick follow-up on ZYNLONTA.

Okay. So – this is Jay. With regard to regulatory, we have an agreement with FDA from the end of Phase I meeting that we would follow patients for 1 year after last patient which we mostly responded to Cami. We're in that time to follow-up right now while the patients were enrolled in January. So we anticipate that we'll have data, obviously, in the first half of 2022. But then we have to review the data, write the BLA, submit the BLA and go from there, probably anticipate a regulatory path in terms of our planning, similar to what we did for ZYNLONTA. But we're not at this point, advising yet, on when we exactly plan to submit that BLA. In terms of KOL feedback, first, with regard to our response. It's important to understand the patients we're treating in this study. So during ICML, we reported on the first 101 patients enrollment study from the point of view of efficacy, and those patients have failed a median of 6 prior lines of therapy. All the patients have failed the checkpoint inhibitor. All except one had failed rituximab without that one - because a mistake on the party investigator and rolling the patient. And over 60% of the patients have failed stem cell transplant as well, but mostly auto - some with all - without, and some with both. And despite all that, we had a 66% overall response rate and a 28% complete response rate, and we didn't reach the median duration response. I think it's important to understand all that in the context of the safety issue of GBS. Clearly, we believe, our advisors believe, our independent data safety mining board believes, and FDA believes that there's enough anti-tumor activity in these very late-stage patients to warrant…

Got it. Thank you. Completely agree there. And as you mentioned, really unparalleled efficacy in those late-stage patients there in conscious. Maybe just that follow-up on ZYNLONTA. Just wondering if you could talk about progress getting ZYNLONTA listed on hospital protocols, especially in some of the largest academic centers. Is that at all associated with getting that permanent J-code, or is this sort of a - just a sort of a step-by-step approach through those large academic hospitals? Thanks. And congrats on the quarter and the progress.

Thanks, Ken. Jennifer, do you want to take that?

Yeah. Thanks, Chris. Kennen, thanks for the question. I think from an access perspective, it all started with the fact that we got our NCCN guidelines less than two weeks after approval with a category 2A listing and recommendation. And that's really helped us accelerate all of our patient access efforts and evidenced in our published medical policies, which we believe will enable faster access for patients, both in the community and the academic centers. We haven't received significant payer pushback, and I think that's reflective of the quality of our data, our documentation such as our AMCP dossier, and the strong execution of our market access and medical teams. And we are, in general, very pleased with our access to date through these medical policies. But it is early days, and we anticipate receiving that permanent J-code in the beginning of 2022. In the meantime, we'll be continuing to support the local community practices through our reimbursement related services, which is called advancing patient support.

And I'm not showing any further questions in the queue. I'd like to turn the call back over to Chris for any closing remarks.

Well, thank you very much for joining our call today, everyone. And we look forward to keeping you updated on our progress. So take care and stay safe. Thanks.

This concludes the program. You may now disconnect.